Daily Stock Analysis, ADMS, Adamas Pharmaceuticals Inc, priceseries

Adamas Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
17.74
Close
17.66
High
17.91
Low
17.52
Previous Close
17.62
Daily Price Gain
0.04
YTD High
19.50
YTD High Date
Jan 6, 2017
YTD Low
14.23
YTD Low Date
Jan 30, 2017
YTD Price Change
1.07
YTD Gain
6.45%
52 Week High
19.50
52 Week High Date
Jan 6, 2017
52 Week Low
12.10
52 Week Low Date
Nov 4, 2016
52 Week Price Change
2.15
52 Week Gain
13.86%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Dec 23. 2014
14.65
Jan 6. 2015
16.51
8 Trading Days
12.72%
Link
LONG
Jun 12. 2015
19.45
Jul 20. 2015
26.77
25 Trading Days
37.63%
Link
LONG
Oct 30. 2015
14.76
Nov 9. 2015
15.88
6 Trading Days
7.58%
Link
LONG
Dec 21. 2015
16.51
Jan 6. 2016
25.17
10 Trading Days
52.43%
Link
LONG
Mar 31. 2016
14.46
Apr 20. 2016
16.97
14 Trading Days
17.38%
Link
LONG
Aug 31. 2016
13.67
Sep 27. 2016
17.30
18 Trading Days
26.56%
Link
LONG
Nov 4. 2016
13.93
Nov 22. 2016
15.37
12 Trading Days
10.32%
Link
LONG
Jun 1. 2017
16.27
Jun 20. 2017
17.23
13 Trading Days
5.91%
Link
Company Information
Stock Symbol
ADMS
Exchange
NasdaqGM
Company URL
http://www.adamaspharma.com
Company Phone
510-450-3554
CEO
Gregory T. Went
Headquarters
California
Business Address
1900 POWELL ST., SUITE 750, EMERYVILLE, CA 94608
Sector
Equity
Industry Category
Drugs
Industry Group
Drugs - Generic
CIK
0001328143
About

Adamas Pharmaceuticals, Inc. operates as a pharmaceutical company, which engages in discovering chrono-synchronous therapies. It involves in the development and commercialization of therapeutics targeting chronic disorders of the central nervous system. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.

Description

Adamas Pharmaceuticals, Inc., a pharmaceutical company, discovers, develops, and sells chrono-synchronous therapies for chronic neurologic disorders. The company's product portfolio comprises ADS-5102, a chrono-synchronous amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its portfolio also comprises of Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease. The company's products under development include ADS-4101, a chrono-synchronous lacosamide therapy that has completed first Phase I clinical study for the treatment of partial onset seizures in patients with epilepsy. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.